Skip to content

Silodosin

Rapaflo, Silodyx, Urorec (silodosin) is a small molecule pharmaceutical. Silodosin was first approved as Rapaflo on 2008-10-08. It is used to treat prostatic hyperplasia in the USA. It has been approved in Europe to treat prostatic hyperplasia. The pharmaceutical is active against alpha-1A adrenergic receptor. In addition, it is known to target alpha-1B adrenergic receptor and alpha-1D adrenergic receptor.
Trade Name Silodyx, Urorec
Common Name Silodosin
Indication prostatic hyperplasia
Drug Class
Silodosin
Get full access now